GlaxoSmithKline PLC Sanofi/GSK to supply EU with 300m COVID 19 doses (8433U)
August 03 2020 - 1:00AM
UK Regulatory
TIDMGSK
RNS Number : 8433U
GlaxoSmithKline PLC
31 July 2020
Issued: 31(st) July 2020, London, UK and Paris, France
GlaxoSmithKline plc
Sanofi and GSK in advanced discussions with European Union to
supply up to 300 million doses of COVID-19 vaccine
-- Discussions relate to vaccine candidate using Sanofi's
recombinant protein-based technology combined with GSK's pandemic
adjuvant system
-- Both companies are committed to making their COVID-19 vaccine
affordable and available globally
Sanofi and GSK are in advanced discussions with the European
Commission (EC) for the supply of up to 300 million doses of a
COVID-19 vaccine. The vaccine candidate developed by Sanofi in
partnership with GSK, is based on the recombinant protein-based
technology used by Sanofi to produce an influenza vaccine, and
GSK's established adjuvant technology. The doses would be
manufactured in European countries including France, Belgium,
Germany and Italy. This marks a key milestone in protecting and
serving the European population against COVID-19.
"Today's announcement helps to ensure that millions of Europeans
will have access to a potential vaccine protecting against
COVID-19, once proven safe and effective. It has been our steadfast
commitment to provide a vaccine that is affordable and accessible
to everyone, and we are grateful to the European Commission for
their ongoing engagement and shared support of this effort," said
Thomas Triomphe, Executive Vice President and Global Head of Sanofi
Pasteur. "Together with GSK, we are working relentlessly to develop
and produce a vaccine to address this global health crisis."
Roger Connor, President of GSK Vaccines added "GSK is proud to
be working in partnership with Sanofi to make this vaccine
available as soon as possible in Europe. Both companies have
significant R&D and manufacturing capability in Europe and are
already working hard to scale up production across our networks.
This announcement from the EC supports our ongoing efforts."
Sanofi is leading the clinical development and registration of
the COVID-19 vaccine and expects a Phase 1/ 2 study to start in
September, followed by a Phase 3 study by the end of 2020. If data
are positive, regulatory approval could be achieved by the first
half of 2021. In parallel, Sanofi and GSK are scaling up
manufacturing of the antigen and adjuvant to produce up to one
billion doses per year overall.
Sanofi and GSK are committed to making the vaccine available
globally
Sanofi and GSK recently signed agreements with the United States
where they have a longstanding partnership with the Biomedical
Advanced Research and Development Authority, and also with the UK
Government. The partners plan to provide a significant portion of
total worldwide available supply capacity in 2021/22 to the global
initiative "Access to COVID -- 19 Tools (ACT) Accelerator," a
global collaboration of leaders of governments, global health
organizations, businesses and philanthropies to accelerate
development, production, and equitable access to COVID-19 tests,
treatments, and vaccines.
GSK commitment to tackling COVID-19
GSK is collaborating with companies and research groups across
the world working on promising COVID-19 vaccine candidates through
the use of our innovative vaccine adjuvant technology. The use of
an adjuvant is of particular importance in a pandemic situation
since it may reduce the amount of vaccine protein required per
dose, allowing more vaccine doses to be produced and therefore
contributing to protecting more people. GSK does not expect to
profit from COVID-19 vaccines during the pandemic phase, and will
invest any short-term profit in coronavirus related research and
long-term pandemic preparedness, either through GSK internal
investments or with external partners.
About GSK
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com/about-us .
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
GSK enquiries:
Media enquiries: Simon Steel +44 (0) 20 8047 (London)
5502
Simon Moore +44 (0) 20 8047 (London)
5502
Kristen Neese +1 804 217 8147 (Philadelphia)
Kathleen Quinn +1 202 603 5003 (Washington
DC)
Analyst/Investor Sarah Elton-Farr +44 (0) 20 8047 (London)
enquiries: 5194
Sonya Ghobrial +44 (0) 7392 (Consumer)
784784
Danielle Smith +44 (0) 20 8047 (London)
0932
James Dodwell +44 (0) 20 8047 (London)
2406
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Frannie DeFranco +1 215 751 4855 (Philadelphia)
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk Factors" in the company's Annual Report on Form 20-F for 2019
and as set out in GSK's Principal risks and uncertainties" section
of the Q2 Results and any impacts of the COVID-19 pandemic .
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCZZGFNLMDGGZM
(END) Dow Jones Newswires
August 03, 2020 02:00 ET (06:00 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024